JP2015504677A - 肝細胞癌治療のためのバイオマーカー - Google Patents

肝細胞癌治療のためのバイオマーカー Download PDF

Info

Publication number
JP2015504677A
JP2015504677A JP2014552323A JP2014552323A JP2015504677A JP 2015504677 A JP2015504677 A JP 2015504677A JP 2014552323 A JP2014552323 A JP 2014552323A JP 2014552323 A JP2014552323 A JP 2014552323A JP 2015504677 A JP2015504677 A JP 2015504677A
Authority
JP
Japan
Prior art keywords
biomarker
tcf
level
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014552323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504677A5 (cg-RX-API-DMAC7.html
Inventor
キム ミラン
キム ミラン
アール．ワンズ ジャック
アール．ワンズ ジャック
ベセメ サラ
ベセメ サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2015504677A publication Critical patent/JP2015504677A/ja
Publication of JP2015504677A5 publication Critical patent/JP2015504677A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014552323A 2012-01-13 2013-01-11 肝細胞癌治療のためのバイオマーカー Pending JP2015504677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586672P 2012-01-13 2012-01-13
US61/586,672 2012-01-13
PCT/US2013/021197 WO2013106686A1 (en) 2012-01-13 2013-01-11 Biomarkers for the treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
JP2015504677A true JP2015504677A (ja) 2015-02-16
JP2015504677A5 JP2015504677A5 (cg-RX-API-DMAC7.html) 2016-03-03

Family

ID=47604231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552323A Pending JP2015504677A (ja) 2012-01-13 2013-01-11 肝細胞癌治療のためのバイオマーカー

Country Status (8)

Country Link
US (1) US8901110B2 (cg-RX-API-DMAC7.html)
EP (1) EP2802877A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015504677A (cg-RX-API-DMAC7.html)
CN (1) CN104737021A (cg-RX-API-DMAC7.html)
AU (1) AU2013202104B2 (cg-RX-API-DMAC7.html)
CA (1) CA2871535A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014008388A (cg-RX-API-DMAC7.html)
WO (1) WO2013106686A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513349A (ja) * 2018-10-14 2022-02-07 ランタン ファーマ インコーポレイテッド イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002752A1 (es) 2006-09-26 2008-07-11 Celgene Corp Soc Organizada Ba Compuestos derivados de 3-(4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir enfermedades tales como cancer, dolor, degeneracion macular, trastorno pulmonar, tr
PE20140983A1 (es) 2011-03-11 2014-08-25 Celgene Corp Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
JP2015531776A (ja) 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
WO2015085172A2 (en) * 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
CN103645259B (zh) * 2013-12-12 2015-03-11 深圳海王药业有限公司 一种同时测定泊马度胺及其有关物质的方法
JP2017533727A (ja) * 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN108048568B (zh) * 2017-12-25 2021-02-02 贵州省人民医院 Plcd4基因作为胃腺癌转移诊断标志物的用途
CN109266747B (zh) * 2018-09-21 2021-07-27 中国医学科学院北京协和医院 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用
WO2020107115A1 (en) * 2018-11-29 2020-06-04 Trillium Therapeutics Inc. Biomarkers for cd47 blockade therapy
CN116064810A (zh) * 2022-11-10 2023-05-05 杭州医学院 CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1166651C (zh) * 2001-06-08 2004-09-15 北京大学药学院 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
WO2011109237A2 (en) * 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMC MEDICINE, vol. Vol. 7, No. 41, JPN6016042605, 2009 *
EXPERIMENTAL CELL RESEARCH, vol. Vol. 317, JPN6016042606, 2011, pages pp. 920-931 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513349A (ja) * 2018-10-14 2022-02-07 ランタン ファーマ インコーポレイテッド イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法

Also Published As

Publication number Publication date
AU2013202104B2 (en) 2015-11-26
US8901110B2 (en) 2014-12-02
WO2013106686A1 (en) 2013-07-18
US20130183675A1 (en) 2013-07-18
CA2871535A1 (en) 2013-07-18
MX2014008388A (es) 2014-11-14
AU2013202104A1 (en) 2013-08-01
EP2802877A1 (en) 2014-11-19
CN104737021A (zh) 2015-06-24

Similar Documents

Publication Publication Date Title
US8901110B2 (en) Use of biomarkers in methods for the treatment of hepatocellular carcinoma
JP7142612B2 (ja) びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
Pantel et al. Liquid biopsy and minimal residual disease—latest advances and implications for cure
Sun et al. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance
US20170242014A1 (en) Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US20180231561A1 (en) Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
Lorenzo-Martín et al. VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma
Werner et al. Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells
CN103026229B (zh) 用于治疗银屑病的生物标志物
JP2020523022A (ja) 免疫療法に反応する肝細胞癌のクラスの検出および治療方法
US20120329061A1 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
Xie et al. Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma
WO2014028445A2 (en) Cereblon isoforms and their use as biomarkers for therapeutic treatment
KR20180052747A (ko) 미만성 거대 b세포 림프종의 치료 방법 및 약물에 대한 반응성의 예측자로서 바이오마커의 용도
US20180251851A1 (en) Ectopic lymphoid structures as targets for liver cancer detection, risk prediction and therapy
US20170182016A1 (en) Biomarkers and use of met inhibitor for treatment of cancer
CN114763574A (zh) Cdkn2a/2b缺失作为预测cdk4/6抑制剂在食管鳞癌中敏感性的生物标志物
JP2011505807A (ja) キナゾリノン化合物による治療をモニタリングするためのバイオマーカー
JP2024511601A (ja) 免疫療法を評価するための手段及び方法
Corrò Dissecting Tumor Heterogeneity and Cancer Stem Cell Properties in Clear Cell Renal Cell Carcinoma
Adams et al. Gastrointestinal Pathology
HK40031046A (en) Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
PL227588B1 (pl) Sposób wykrywania in vitro agresywnych komórek nowotworowych o fenotypie macierzystym i/lub mezenchymalnym, zestaw do wykrywania oraz zastosowanie sposobu do wykrywania in vitro agresywnych komórek nowotworowych o fenotypie macierzystym i/lub mezenchymalnym do przewidywania przebiegu raka piersi
JP2009060821A (ja) Ａｃｃ亜分類の検出方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170801